Rebecca Goodrich

Emraclidine as a Novel Positive Allosteric Modulator Targeting M4 Muscarinic Receptors: Results From a Phase 1b Trial in Patients With Schizophrenia

Abstract: Background: Emraclidine is a novel, highly selective, M4 muscarinic receptor positive allosteric modulator in development for treating schizophrenia. Here, we describe safety, t...

Koji Takahashi , PhD;

Rebecca Goodrich ;

01/19/2023

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

March 17 ⁠–⁠ March 19

See Full Calendar

Rebecca Goodrich

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products